07:00 , Apr 12, 2010 |  BioCentury  |  Strategy

Altheos Mines its Rho-lodex

After concluding that all the interesting new projects in the U.S. and Europe had been picked over, the founders of Altheos Inc. turned to Asia to find assets for in-licensing. Based on the strength of...
07:00 , Jun 2, 2008 |  BioCentury  |  Finance

Ebb & Flow

Southern exposure By Stacy Lawrence & Mike Ward With only one Phase I compound left in its pipeline, cancer company Sonus (NASDAQ:SNUS) last week announced a 50-50 reverse merger with private Canadian cancer company OncoGenex...
07:00 , Jul 16, 2007 |  BioCentury  |  Product Development

Wounds: Not open & shut

The failure of a series of wound healing agents, combined with disappointing sales for the few products that were approved, eroded interest in the space in the 1990s. But efforts now have been rekindled by...
08:00 , Feb 26, 2007 |  BC Week In Review  |  Company News

Athenagen neurology, dermatology, ophthalmic news

The company changed its name to CoMentis Inc. Athenagen Inc. , South San Francisco, Calif.   Business: Neurology, Dermatology, Ophthalmic  ...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Clinical News

Mecamylamine: Phase II start

This quarter, Athenagen will begin a double-blind, placebo-controlled, international Phase II trial in 330 patients. Athenagen Inc. , South San Francisco, Calif.   Product: Mecamylamine (ATG3)   Business: Ophthalmic   Molecular target: Nicotinic acetylcholine receptor...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Clinical News

Mecamylamine: Phase I data

In a double-blind, placebo-controlled, U.S. Phase I trial in 80 healthy volunteers, ATG3 was safe and did not cause systemic side effects. The compound was dosed twice-daily for 14 days. Athenagen Inc. , South San...
08:00 , Jan 29, 2007 |  BioCentury  |  Product Development

Back-of-the-eye pipeline

Back-of-the-eye pipeline Back-of-the-eye pipeline Selected products in development for three major ophthalmic indications: diabetic macular edema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR). (A) In October, Eli Lilly (LLY) said it would appeal...
08:00 , Jan 29, 2007 |  BioCentury  |  Product Development

Optical focus

For years, the ophthalmic space was more or less moribund as far as biotech was concerned, populated mainly by old-line companies peddling old-line treatments. But both the aging of the population and the rise in...
08:00 , Oct 30, 2006 |  BC Week In Review  |  Company News

Athenagen management update

Athenagen Inc. , South San Francisco, Calif.   Business: Cardiovascular, Cancer, Ophthalmic   Hired: John Anthony as VP of non-clinical development, formerly senior director of Schering-Plough Corp.'s Schering-Plough Research Institute; Carl Grove as VP of...
07:00 , Oct 2, 2006 |  BC Week In Review  |  Company News

Athenagen board of directors update

Athenagen Inc. , South San Francisco, Calif.   Business: Cardiovascular, Cancer, Ophthalmic   Appointed: Dennis Henner, a managing director at Clarus Ventures  ...